PET-CT vs contrast-enhanced CT: What is the role for each after chemoradiation for advanced oropharyngeal cancer?

Head and Neck

Volumn 28, Issue 6, 2006, Pages 487-495

  Chen, Amy Y ^a   Vilaseca, Isabel ^b   Hudgins, Patricia A ^a   Schuster, David ^a   Halkar, Ragheev ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Chemoradiation; Computed tomography; Oropharyngeal carcinoma; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; NECK DISSECTION; OROPHARYNX CANCER; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NECK; NEOPLASM, RESIDUAL; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33744909580     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20362     Document Type: Article

References (32)

1. Bailet JW, Abemayor E, Jabour BA, et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-288.
2. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-(F-18) fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135-141.
3. Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. In J Radiat Oncol Biol Phys 1995;31:1141-1164.
4. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-1495.
5. McGuirt WF, Greven K, Williams D III, et al. Pet scanning in head and neck oncology: a review. Head Neck 1998;20:208-215.
6. Jabour BA, Choi Y, Hoh CK, et al. Extracraneal head and neck: PET imaging with 2-(F-18) fluoro 2-deoxy-D-glucose and MRI imaging correlation. Radiology 1993; 186:27-35.
7. Rege S, Maass BS, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:1307-1310.
8. Bailet JW, Sercarz JA, Abemayor E, Anzai Y, Lufkin RB, Hoh CK. The use of positron emission tomography or early detection of recurrent head and neck carcinoma in post-radiotherapy patients. Laryngoscope 1995;105:135-139.
9. Greven KM, Wiliams DW, Keyes JW, et al. Positron emission tomography before an after high dose irradiation in patients with head and neck carcinoma. Cancer 1994;74:1355-1359.
10. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy- glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001;23:933-941.
11. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nuc Med 1998;29:1521-1525.
12. Haberkorn U, Strauss LG, Reisser Ch, et al. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-1558.
13. Chaiken L, Rege S, Hoh C. Positron emission tomography with fluordeoxyglucose to evaluate tumor response and control after radiotherapy. Int J Radiat Oncol Biol Phys 1993;27:455-464.
14. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 1999;26:767-773.
15. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using (F-18) fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666-674.
16. Schechter NR, Gillenwater AM, Byers RM, et al. Can positron emission tomography improve the quality of care for head and neck cancer patients? Int J Radiat Oncol Biol Phys 2001;51:4-9.
17. Bataini JP, Jaulerry C, Brunin F, Ponvert D, Ghossein A. Significance and therapeutic implications of tumor regression following radiotherapy in patients treat for squamous cell carcinoma of the oropharynx and pharyngolarynx. Head Neck 1990;12:41-49.
18. McGuirt WF, Keyes JW Jr, Geisinger KR, et al. Positron emission tomography in the evaluation of laryngeal carcinoma. An Otol Rhinol Laryngol 1995;104:274-278.
19. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110:1493-1497.
20. Paulus P, Sambon A, Vivegnis D, et al. 18FDG-PET for the assessment of primary head and neck tumors. Clinical, computed tomography, and histopathologic correlation in 38 patients. Laryngoscope 1998;108:1578-1583.
21. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880-885.
22. Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-(F-18) fluoro-2-deoxy-D-glucose. Radiology 1995;197:205-211.
23. Greven KM, Williams DW, McGuirt WF, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23:942-946.
24. Farber LA, Bernard F, Machtay M, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-deoxy-D- glucose positron emission tomography. Laryngoscope 1999;109:970-975.
25. Kitagawa Y, Sano K, Nishizawa S, et al. FDG-PET for prediction of tumor aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med 2003;30:63-71.
26. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997;22:209-214.
27. Myers LL, Wax MK. Positron emission tomography in the evaluation of negative neck in patients with oral cavity cancer. J Otolaryngol 1998;6:342-347.
28. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001;26:131-135.
29. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;197:205-211.
30. Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eu J Cancer 2000;36:858-867.
31. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651-658.
32. Rogers JW, Greven KM, McGuirt WF, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys 2004; 58:694-697.